MGMT and glioblastoma: Moreover, epigenetic modifications, such as the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter, show sex-specific effects on GBM progression and therapy response, with a hypermethylated MGMT promoter status in about 80% of female patients vs. only 27% in men.